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Myeloid precursor cell reprogramming into a myeloid-derived suppressor cell (MDSC)
contributes to high mortality rates in mouse and human sepsis. S100A9 mRNA
and intracellular protein levels increase during early sepsis and remain elevated in
Gr1+CD11b+ MDSCs after pro-inflammatory sepsis transitions to the later chronic
anti-inflammatory and immunosuppressive phenotype. The purpose of this study was
to determine whether intracellular S100A9 protein might sustain Gr1+CD11b+ MDSC
repressor cell reprogramming during sepsis. We used a chronic model of sepsis in
mice to show that S100A9 release from MDSCs and circulating phagocytes decreases
after early sepsis and that targeting the S100a9 gene improves survival. Surprisingly,
we find that intracellular S100A9 protein translocates from the cytosol to nucleus
in Gr1+CD11b+ MDSCs during late sepsis and promotes expression of miR-21 and
miR-181b immune repressor mediators. We further provide support of this immunosuppression pathway in human sepsis. This study may inform a new therapeutic target
for improving sepsis outcome.
Keywords: sepsis, myeloid-derived suppressor cells, immune suppression, S100A9, myeloid cell reprogramming

INTRODUCTION
Sepsis is the leading cause of death among critically ill patients (1, 2). The initial/acute phase of
sepsis, which may cause cardiovascular collapse and rapid death, more commonly progresses to
chronic sepsis, which is clinically characterized by innate and adaptive immune incompetence
and organ failure (3–5). This chronic sepsis state has been named the persistent inflammationimmunosuppression and catabolism syndrome (PICS) (6). Although well recognized and
characterized, the molecular events that promote this unresolving state of sepsis are unclear,
but sustained presence of a cell phenotype called myeloid-derived suppressor cells (MDSCs)
likely contributes to PICS (7). This broad-based immune-suppressor state with organ failure is
typified by repressed effector phenotypes of CD4+ and CD8+ T-cells, circulating, splenic, and
myeloid- dendritic, NK cells and other heterogeneous innate and adaptive immune cells (4, 8).
PICS clinical phenotype is reflected by persistent bacterial infection and reactivation of latent
viruses (4, 6). Importantly, the immune-suppressor phenotype typifies endotoxin tolerance and
develops within hours of the early hyper-inflammatory cytokine-mediated “cytokine storm”
(9, 10). Other characteristics are increased apoptosis of different cell types (4) and repressed
mitochondrial fueling by glucose and fatty acids (11, 12).
Calcium-binding proteins S100A8 and S100A9 are markedly increased during sepsis (13), and
their elevated levels in circulating innate immune phagocytes during sepsis may contribute to acute
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and chronic inflammation (14, 15). S100A8 and S100A9 are
mainly expressed in the myeloid lineage cells (16), including
monocytes and granulocytes, but not resident tissue macrophages (15) and are dominant in the systemic circulation. The
two proteins are also expressed in early stages of myeloid differentiation and decline during maturation, but remain elevated
in neutrophils (17). S100A8/A9 protein complexes are mostly
cytosolic, where they are recruited to the plasma membrane and
secreted after protein kinase C (PKC) activation and cytoskeletal
rearrangement following phagocytosis (14).
Most studies of S100A8/A9 proteins emphasize them as
pro-inflammatory mediators, which amplify acute and chronic
inflammatory processes during phagocyte activation (14, 18, 19).
S100A8/A9 heterodimers released at sites of inflammation
induce more S100A8/A9 in phagocytes, thereby acting as a
feedforward loop to amplify the local inflammatory reaction
(15, 20). Heterodimeric S100A8/A9 binds to and activates tolllike receptor 4 (TLR4), a master “alarmin” sensor (21). S100A8/
A9 heterodimers are secreted readily from bone marrow cells
and blood monocytes following bacterial lipopolysaccharide
(LPS)-mediated activation of TLR4 (14). Further supporting
pro-inflammatory functions is the finding that S100A9−/− mice
exhibit blunted LPS-induced endotoxemia (21). In contrast,
there are reports of anti-inflammatory properties of S100A8/
A9 showing that intraperitoneal injections of S100A8/A9 heterodimers into rat after LPS administration reduces serum levels
of pro-inflammatory IL-6 and nitrite (22). In addition, because
S100A8/A9 supports phagocyte migration, inhibiting S100A8/
A9 would have anti-inflammatory potential (14). An important
finding suggesting a repressor function is that immune repressor
mediator IL-10 induces S100A8 in human macrophages (23).
Here, we report a new function for S100A9 that further supports the repressor concept of S100A8/A9. We find that mice
genetically deficient for S100A9 are protected from late sepsis
deaths by preventing MDSC repressor activity. We further find
that S100A8/A9 proteins are released from phagocytes during
early, but not late sepsis, and that cytosolic S100A9 translocates
from cytosol to the nucleus of MDSCs. Mechanistically, our data
support that nuclear S100A9 promotes the expression of known
immunosuppressive miR-21 and miR-181b (24). The findings of
this study support therapeutic targeting of S100A9 for chronic
sepsis.

strain (work performed by TransViragen, Chapel Hill, NC, USA).
Heterozygous animals were intercrossed to generate homozygous
(−/−) mutant animals for study. The mice were bred and housed
in a pathogen-free facility in the Division of Laboratory Animal
Resources. Wild-type male C57BL/6J mice, 8–10 weeks were
purchased from Jackson Laboratory (Bar Harbor, ME, USA) and
used as controls, and were acclimated to the new environment
for a week before surgery. All experiments were conducted in
accordance with National Institutes of Health guidelines and were
approved by the East Tennessee State University Animal Care and
Use Committee.

Polymicrobial Sepsis

Polymicrobial sepsis was induced in male wild-type and S100A9
knockout mice, 8–10 week old, by cecal ligation and puncture
(CLP) as described previously (26). Briefly, mice were anesthetized via inhalation with 2.5% isoflurane (Abbott Laboratories,
Abbott Park, IL, USA). A midline abdominal incision was made
and the cecum was exteriorized, ligated distal to the ileocecal
valve, and then punctured twice with a 23-gauge needle. A
small amount of feces was extruded into the abdominal cavity.
The abdominal wall and skin were sutured in layers with 3-0
silk. Sham-operated mice were treated identically except that
the cecum was neither ligated nor punctured. Mice received
(i.p.) 1 ml lactated Ringers plus 5% dextrose for fluid resuscitation. To induce sepsis that develops into early and late phases,
mice were subcutaneously administered antibiotic (Imipenem;
25 mg/kg body weight) or an equivalent volume of 0.9% saline.
To establish intra-abdominal infection and approximate the
clinical condition of early human sepsis where there is a delay
between the onset of sepsis and the delivery of therapy (27),
injections of Imipenem were given at 8 and 16 h after CLP. Based
on our experience, these levels of injury and manipulation create
prolonged infections with high mortality (~60–70%) during the
late/chronic phase (26).
The presence of early sepsis was confirmed by transient systemic bacteremia and elevated cytokine levels in the first 5 days
after CLP. Late/chronic sepsis (after day 5) was confirmed by
enhanced peritoneal bacterial overgrowth and reduced circulating pro-inflammatory cytokines. Table S1 in Supplementary
Material includes the CLP mice that were used in the study.

Sepsis Patients

MATERIALS AND METHODS

Patients 18 years of age or older who were admitted to Johnson
City Medical Center and Franklin Woods Hospital in Johnson
City, Tennessee, and who were diagnosed with sepsis or septic
shock were included in the study. Sepsis was defined as the presence of suspected or documented infection with at least two of
the following criteria: core temperature >38°C or <36°C; heart
rate >90 beats/min; respiratory rate >20 breaths/min or arterial
blood partial pressure of carbon dioxide <32 mmHg; or white
blood cell count >12,000 cells/mm3 or <4,000/mm3. Septic shock
was defined as sepsis with persisting hypotension requiring
vasopressors to maintain MAP ≥65 mmHg and having a serum
lactate >2 mmol/L despite adequate volume resuscitation (28).
Patients presented with infections related to Gram-negative or
Gram-positive bacteria. The primary infection included urinary

Mice

The S100a9 mutant mouse strain [S100a9tm1(KOMP)/VLcg] used for
this study was created from ES cell clone 12158a-E1, generated
by Regeneron Pharmaceuticals (Eastview, NY, USA), and made
into live mice by the KOMP Repository1 and the Mouse Biology
Program2 at the University of California Davis. Methods used to
create the Velocigene targeted alleles have been published (25).
Cryopreserved sperm from the KOMP repository was used for
in vitro fertilization of C57BL/6NJ oocytes to reconstitute the
1
2

http://www.komp.org.
http://www.mousebiology.org.
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tract infection, blood stream infection, and respiratory tract
infection. Patients had at least 1 comorbid condition, including
nephropathy, psoriasis, splenectomy, colon cancer, or pulmonary
aspergillosis. Patients with leukopenia due to chemotherapy or
glucocorticoid therapy or HIV infection were excluded from
the study. Patients were divided into two categories: early sepsis
and late sepsis, relative to the day of sepsis diagnosis. The early
septic group included patients within 1–5 days of sepsis diagnosis.
Those who have been septic for more than 6 days were considered
late septic. For this latter group, blood was drawn at days 6–68
after sepsis diagnosis. Blood samples obtained from healthy
control subjects were supplied by Physicians Plasma Alliance
(Gray, TN, USA). The study was approved by the Institutional
Review Board (IRB) of the East Tennessee State University (IRB#:
0714.6s). Signed informed consent was obtained from all subjects.

layer) and 2.5 ml Histopaque-1077. Samples were centrifuged at
700g for 30 min at room temperature. Plasma was collected and
stored at −20°C for later analysis. The upper cell layer containing
PBMCs was removed and washed with PBS. The lower cell layer
containing granulocytes was washed with PBS three times by
centrifugation at 200g for 10 min. With this method, erythrocytes and platelets are removed by the low speed centrifugation
during the washing steps. Monocytes were then isolated from the
PBMCs by positive selection with anti-Ly6C antibody and combined with the granulocytes (mainly neutrophils), to represent
the phagocyte population used in the study. In some experiments,
granulocytes were used separately.

Peritoneal Bacterial Quantification

Immediately after mice were euthanized, the peritoneal cavity
was lavaged with 5 ml PBS. The lavage was cleared by centrifugation and plated on trypticase soy agar base (BD Biosciences,
Sparks, MD, USA). The plates were incubated for 24 h at 37°C
under aerobic conditions. The plates were read by a microbiologist and the colony-forming units (CFUs) were enumerated.

Immunoblotting

Whole cell lysate, cytoplasmic, and nuclear proteins were prepared as described previously (29). Equal amounts of protein
extracts were mixed with 5× Laemmeli sample buffer, separated
by SDS-10% polyacrylamide gel (Bio-Rad, Hercules, CA, USA)
and subsequently transferred to nitrocellulose membranes
(Thermo Fisher Scientific, Waltham, MA, USA). After blocking
with 5% milk in Tris-buffered saline/Tween-20 for 1 h at room
temperature, membranes were probed overnight at 4°C with the
following primary antibodies: anti-goat S100A8 (sc-8112; Santa
Cruz Biotechnology, Santa Cruz, CA, USA); anti-Rabbit S100A9
(ab75478) and anti-mouse S100A8/A9 heterodimer (ab17050),
both from Abcam (Cambridge, MA, USA); anti-Rabbit phospho-threonine113 S100A9 (12782; Signalway Antibody LLC.,
College Park, MD, USA); anti-Rabbit p38 (sc-7149) and p-p38
(sc-17852-R), anti-mouse phospho-serine 657 PKC (sc-377565),
anti-Rabbit phospho-serine 660 PKC (sc-11760-R) (Santa Cruz
Biotechnology). The S100A8/9 heterodimer was detected under
non-denaturing conditions. After washing, blots were incubated
with the appropriate HRP-conjugated secondary antibody (Life
Technologies, Grand Island, NY) for 2 h at room temperature.
Proteins were detected with the enhanced chemiluminescence
detection system (Thermo Fisher Scientific, Waltham, MA,
USA), the bands were visualized using the ChemiDoc XRS
System (Bio-Rad), and the images were captured with the Image
Lab Software V3.0. Membranes were stripped and re-probed
with actin (Sigma-Aldrich, Saint Louis, MO, USA) antibody as
a loading control.

Isolation of Gr1+CD11b+ Cells

Gr1+CD11b+ cells were isolated from the bone marrow or spleens
by use of magnetically assisted cell sorting according to the
manufacturer’s protocol (Miltenyi Biotech, Auburn, CA, USA).
The bone marrow was flushed out of the femurs with RPMI-1640
medium (without serum) under aseptic conditions (26). The
spleens were dissociated in RPMI-1640 medium. A single cell
suspension of the bone marrow or spleens was made by pipetting
up and down and filtering through a 70-µm nylon strainer, followed by incubation with erythrocyte lysis buffer and washing.
To purify total Gr1+CD11b+ cells, the single cell suspension was
subjected to positive selection of the Gr1+ cells by incubating
with biotin-coupled mouse anti-Gr1 antibody (Clone RB6-8C5;
eBioscience, San Diego, CA, USA) for 15 min at 4°C. Cells were
then incubated with anti-biotin magnetic beads for 20 min
at 4°C and subsequently passed over a MS column. Purified
Gr1+CD11b+ cells were then washed and resuspended in sterile
saline. The cell purity was more than 90% as determined by flow
cytometry.

Flow Cytometry

Gr1+CD11b+ cells were stained by incubation for 30 min on ice
in staining buffer (PBS plus 2% FBS) with the following mouse
antibodies: fluorescein isothiocyanate (FITC)-conjugated antiGr1, phycoerythrin (PE)-conjugated anti-CD11b, allophycocyanin-conjugated anti-F4/80, PE-conjugated anti-CD11c,
FITC-conjugated anti-MHC II. CD4+ T cells were stained with
PE-conjugated anti-CD4 antibody (all antibodies were from
eBioscience, San Diego, CA, USA). An appropriate isotypematched control was used for each antibody. After washing, the
samples were analyzed by an Accuri C6 flow cytometer (BD,
Franklin Lakes, NJ, USA).

Blood Phagocytes and Plasma

Mice were subjected to deep anesthesia with isoflurane and
blood was collected via cardiac puncture using EDTA-rinsed
syringes. Blood was diluted fivefold (up to 2.5 ml) in phosphatebuffered saline containing 0.3 mM EDTA. To obtain phagocytes
(mainly monocytes and polymorphonuclear neutrophils), we first
isolated peripheral blood mononuclear cells (PBMCs) and granulocytes by gradients of Histopage-1077 and Histopaque-1119
following the manufacturer’s instructions (Sigma-Aldrich, Saint
Louis, MO, USA). Briefly, diluted blood (2.5 ml) was layered in a
15-ml conical tube containing 2.5 ml Histopague-1119 (bottom
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Spleen CD4+ T cells were isolated from normal (naive) mice by
positive selection using magnetic beads (Miltenyi). Cells were
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background. A diagram showing the S100a9 knockout allele
and location of the PCR genotyping primers is presented in
Figure 1.
Our model of polymicrobial sepsis with fluid resuscitation
and limited antibiotic treatment develops into early and late sepsis
phases (26). We previously showed that mortality is higher during
the late/chronic phase and is mainly due to immunosuppression
(30). Sepsis was induced by CLP, and survival was reported for
a 4-week period. Mice moribund during early sepsis (defined as
the first 5 days after CLP) or late sepsis (the time after day 6) were
sacrificed and analyzed. Because most of the S100A9 knockout
mice survived late sepsis, for each moribund and sacrificed mouse
from the wild-type group, a healthy appearing mouse from the
S100A9 knockout group was also sacrificed at the same time, but
is reported as “survivor.”
As shown in Figure 2A, 100% of the wild-type mice died
before the end of the 4-week period. Lack of S100A8/A9 proteins
slightly improved survival during early sepsis at days 3–5, with
14.7 and 15.2% increases in survival, respectively, at days 3 and 5
compared to the wild-type mice. Of note, survival in the late sepsis
phase was improved by 80% in the S100A9 knockout (S100A9−/−)
vs. wild-type mice (Figure 2A). As expected, S100A8 mRNA, but
not protein, was detected in phagocytes from septic wild-type and
S100A9 knockout mice (Figures 2B,C).

fluorescently labeled with carboxy-fluorosceindiacetate, succinimidyl ester (CFSE) dye using the Vybrant CFDA SE Cell Tracer
Kit (Invitrogen Molecular Probes, Eugene, OR, USA). Cells were
incubated for 10 min at room temperature with 10 µM CFSE
dye and then cocultured (at 1:1 ratio) with the Gr1+ CD11b+
cells, which were isolated from the bone marrow of sham or late
septic mice. T cell proliferation was induced by the stimulation
with an anti-CD3 plus anti-CD28 antibody (1 μg/ml/each). After
3 days, cells were harvested and CD4+ T cell proliferation was
determined by the step-wise dilution of CFSE dye in dividing
CD4+ T cells, using flow cytometry.

Real-time PCR

Quantitative real-time qPCR was used to determine the expression
levels of S100A8, S100A9, miR-21, and miR-181b in Gr1+CD11b+
cells. For S100A8 and S100A9, total RNA was isolated using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and amplified using
QuantiNova SYBR Green RT-PCR kit and QuantiTect Primer
Assays specific to S100A8 and S100A9 (Qiagen, Germantown,
MD). The target RNA: 18S rRNA ratio was calculated using the
2−ΔΔCt cycle threshold.
For miR-21 and miR-181b measurements, miRNA-enriched
RNA was isolated and measured using miScript SYBR Green
PCR kit and miScript Primer Assays specific to miR-21 and
miR-181b (Qiagen). The expression level was calculated using
the 2−ΔΔCt cycle threshold method after normalization to the
endogenous U6 RNA as an internal control.

S100A9 Knockout Attenuates Late Sepsis
Immunosuppression

Early/acute septic mice display elevated levels of proinflammatory cytokines such as TNFα, whereas late/chronic
septic mice are known to progress to an anti-inflammatory/
immunosuppressive phenotype characterized by elevated levels
of IL-10 and increased peritoneal bacterial growth (30). We

Ca2+ Assay

Intracellular calcium levels in phagocytes were measured using
the cell-based Fluo-4 NW Calcium Assay kit according to the
manufacturer’s protocol (Molecular Probes, Eugene, OR, USA).

ELISA

Specific ELISA kits were used to measure the levels of S100A8,
S100A9 (MyBioSource, San Diego, CA, USA) and S100A8/A9
heterodimer (R&D Systems, Minneapolis, MN, USA). Levels
of TNFα and IL-10 were determined using specific ELISA kits
(eBioscience) according to the manufacturer’s instructions. Each
sample was run in duplicate.

Statistical Analysis

The Kaplan–Meier survival curve was plotted by use of a
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) and
survival significance was determined by a log-rank test. Other
data were analyzed by Microsoft Excel, V3.0. Data are expressed
as mean ± SD. Differences among groups were analyzed by a
two-tailed Student’s t-test for two groups and by ANOVA for multiple groups. P values < 0.05 were considered statistically significant.

RESULTS

FIGURE 1 | Targeted deletion of the S100a9 gene. (A) The S100a9 gene
was inactivated by insertion of the lacZ-neo cassette into exon 2 immediately
next to the transcription start site (ATG). (B) Nucleotide sequences of the
genotyping primers used for detection of the WT and KO alleles and agarose
gel electrophoresis of the PCR products generated from Gr1+CD11b+ cells
(right). M, size marker; WT, wild-type; KO, knockout.

S100A8/9 Play a Major Role in Sepsis
Mortality

To examine the physiologic contribution of S100A8/A9 to
sepsis, we created an S100A9 knockout mouse on a C57BL/6
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significantly higher in wild-type mice. During late sepsis,
however, TNFα significantly decreased in both wild-type and
knockout mice. In contrast, wild-type and S100A9 knockout
mice produced small amounts of the immunosuppressive IL-10
during early sepsis, but significantly increased during late sepsis
in the wild-type mice and not in knockout mice (Figure 3A).
Peritoneal bacteria significantly increased in wild-type mice
during late sepsis, but diminished in the S100A9 knockout mice
(Figure 3B). These results support that improved sepsis survival
in the S100A9 knockout mice parallels reduced immunosuppressive cytokine production and increased local bacterial
clearance. These findings suggest that S100A9 expression may
promote late sepsis immunosuppression and predicts that its
genetic reduction would limit MDSC repressor cells.

S100A9 Deficiency Prevents MDSC
Development during Sepsis

Because S100A9 knockout prevented late sepsis deaths, we first
tested whether S100A9 deficiency affects MDSC generation
during sepsis response. We determined MDSC numbers in sham
and septic mice. Numbers of Gr1+CD11b+ cells significantly
increased in the bone marrow in wild-type and S100A9 knockout mice in early sepsis (Figure 4A), as we reported previously
(30), but were significantly decreased in the S100A9 knockout
mice in late sepsis (Figure 4A). We observed similar patterns of
Gr1+CD11b+ cell expansion in the spleens, but the numbers were
far less compared with the bone marrow (Figure 4B).
It is known that Gr1+CD11b+ MDSCs from late, but not
early, septic mice suppress T cell activation and proliferation
(31). Accordingly, we investigated effects of Gr1+CD11b+ cells
on T cell proliferation and activation in wild-type and S100A9
knockout mice, as assessed by IFNγ production. Spleen CD4+
T cells from naive, wild-type mice were cocultured with
Gr1+CD11b+ cells from sham (as a control) and septic mice,
and then stimulated with anti-CD3 and anti-CD28 antibodies
in order to activate the antigen receptor and assess immune
competence. Gr1+CD11b+ cells from early septic wild-type
or S100A9 knockout mice could not suppress CD4+ T cell
proliferation but exhibited slightly reduced IFNγ production
(Figures 4C,D). In contrast, Gr1+CD11b+ cells from late septic
wild-type mice significantly decreased CD4+ T cell proliferation
and IFNγ production compared with Gr1+CD11b+ cells from
sham or early septic mice. Moreover, Gr1+CD11b+ cells from
late septic knockout mice could not inhibit T cell proliferation,
nor could they reduce IFNγ production after antigen stimulation by anti-CD3 and anti-CD28 (Figures 4C,D). These results
suggest that S100A9 promotes MDSC repressor function during
chronic sepsis. Next, we investigated the S100A8/9 biology in
septic mice.

FIGURE 2 | The S100A9 knockout improves late sepsis survival. Sepsis was
induced by cecal ligation and puncture (CLP) using a 23-gauge needle, and
mice were given antibiotics with fluid resuscitation. With this injury and
treatment, sepsis develops into an early phase (defined as days 1–5 after
CLP) and a late phase (day 6 thereafter). (A) Kaplan–Meier survival curve
(n = 22 mice per group). Mortality was monitored for 28 days and the deaths
were separated into two categories: early deaths (those occurring on days
1–5) and late deaths (those occurring on days 6–28). All moribund mice
suffered significant weight loss (>30%), hypothermia (<34°C) and loss of
righting reflex. Each group included 30 mice. Mice that died spontaneously
(i.e., did not meet the criteria for morbundity) were excluded. The results are
representative of three experiments. Mice used in all subsequent experiments
were pooled from three experiments. (B) S100A8 and S100A9 mRNA levels.
Blood was collected from moribund mice that were killed at days 1–5
(representing early sepsis) or days 6–25 post CLP (representing late sepsis).
During late sepsis, a corresponding number of surviving, healthy appearing
S100A9 KO mice were also sacrificed and analyzed at the same time, but are
reported as “survivors.” Phagocytes were isolated from peripheral blood by
gradients of Histopage-1077 and Histopaque-1119. Total RNA was extracted
and analyzed by real-time PCR. The S100A8 and S100A9 expression levels
were normalized to 18S rRNA. Data are means ± SD (n = 6–8 mice per
group), and are representative of three experiments (*p < 0.001 vs. sham;
**p < 0.001 vs. S100A8). (C) Levels of S100A8 and S100A9 proteins in
phagocyte lysate were determined by immunoblotting. The membranes were
first incubated with anti-S100A8 antibody, followed by anti-S100A9 antibody.
Cells were pooled from 2–3 mice per group, and the results are
representative of two immunoblots. WT, wild-type; KO, knockout.

S100A8/A9 Secretion from Phagocytes
Decreases in Late Septic Mice

measured levels of IL-10 and the pro-inflammatory cytokine
TNFα in the plasma, as well as levels of peritoneal bacteria.
As shown in Figure 3A, TNFα levels increased in both wildtype and S100A9 knockout mice during early sepsis, but were
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assessed these proteins during sepsis. First, we tested whether
S100A8/A9 proteins accumulate in plasma obtained from sham
and septic mice during early and late sepsis. Both S100A8/
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FIGURE 3 | The S100A9 knockout mice do not develop immunosuppressive phenotypes during late sepsis. (A) Decreased production of the immunosuppressive
cytokine IL-10 in S100A9 knockout mice during late sepsis. Blood was collected from moribund mice undergoing early and late sepsis. The early and late sepsis
groups, respectively, included mice that were killed between days 1–5 and 6–28 after cecal ligation and puncture. During late sepsis, a corresponding number of
surviving, healthy appearing S100A9 KO mice were also killed and analyzed at the same time. Plasma was collected and levels of TNFα and IL-10 were measured
by ELISA. (B) Diminished peritoneal bacterial growth in the S100A9 knockout mice during late sepsis. Mice were subjected to peritoneal lavaging immediately after
sacrifice. Lavage bacteria were cultured on tryptase soy agar plates and the colony-forming units (CFUs) were enumerated 24 h later. Data are means ± SD (n = 5–7
mice per group), and are representative of three experiments. *p < 0.0001 vs. sham; #p < 0.05 vs. sham; **p < 0.0002 vs. early sepsis (TNFα) or late sepsis WT
(IL-10); §p < 0.001 vs. early sepsis or late sepsis WT (B). WT, wild type; KO, knockout.

S100A9 Protein Phosphorylation and
Dimerization Is Inhibited, and the
Protein Is Translocated to the Nucleus
in Late Sepsis Gr1+CD11b+ MDSCs

A9 protein levels increased in plasma during early sepsis, but
decreased during late sepsis (Figure 5A). Similar patterns of
S100A8/A9 heterodimer secretion occurred (data not shown).
We then determined whether S100A8 and S100A9 gene expressions
paralleled plasma levels during early and late sepsis by measuring
mRNA and protein in circulating phagocytes (mainly monocytes
and neutrophils), the primary source of S100A8/A9 (14). S100A8/
A9 mRNA and protein levels, in contrast to plasma levels, were
similar in circulating phagocytes during early and late septic mice
(Figures 5B,C). These results support that S100A8/A9 expression
increases in mature phagocytes during early and late sepsis, while
protein secretion decreases or extracellular clearance increases.

To probe what prevents S100A8/A9 release from late sepsis
Gr1+CD11b+ cells, we examined S100A9 protein phosphorylation and subcellular localization. S100A9 protein is phosphorylated by p38 MAPK (32, 33) on threonine113 at the C-terminal
domain in a Ca2+-dependent manner (34), a modification that
facilitates translocating S100A8/A9 complex from the cytosol to
plasma membrane for secretion (35). Immunoblotting showed
that S100A9 protein was phosphorylated on threonine 113 and
formed heterodimers with S100A8 in early, but not late sepsis
Gr1+CD11b+ cells (Figure 7A), despite activation of p38 MAPK
(Figure 7B).
Secretion of S100A8/A9 complexes is also an energy-dependent
process, requires activation of PKC and Ca2+-dependent signaling to support S100A8/A9 interactions with microtubules and
translocation to plasma membrane and subsequent release (16).
We detected similar phosphorylation (activation) of PKC in
early and late sepsis Gr1+CD11b+ cells (Figure 7C). In addition,
Ca2+ binding increases the stability of the S100A8/A9 protein
complexes (36). An assay of intracellular calcium did not reveal
significant differences in the Ca2+ levels between early and
late sepsis Gr1+CD11b+ cells (Figure 7D). We also examined
subcellular localization of S100A8/A9 proteins. S100A8/A9
proteins are mainly localized in the cytosol (35). As shown in
Figure 7E, S100A9 protein was mainly detected in the cytosol
in Gr1+CD11b+ cells in early sepsis, but was mainly localized in
the nucleus in late sepsis. We did not detect phospho-S100A9
protein in the nucleus by western blot in early or late sepsis
Gr1+CD11b+ cells (Figure 7E), suggesting that S100A9 protein
accumulates in the nucleus in an unphosphorylated form.
In addition, we detected S100A8 protein mainly in the cytosol

S100A9 Secretion from Gr1+CD11b+ MDSC
Decreases during Late Sepsis

The results presented above suggested that secreted or intracellular S100A8/A9 protein may be needed to generate the MDSC
repressor phenotype. To examine this question, we first measured
mRNA and protein levels in Gr1+CD11b+ cells isolated from the
bone marrow of wild-type mice with or without sepsis. S100A8/
A9 mRNAs similarly increased during early and late sepsis
(Figure 6A). Immunoblotting revealed that S100A8/A9 protein
levels also increased during early sepsis and accumulated in late
sepsis Gr1+CD11b+ cells (Figure 6B). We next studied release of
S100A8/A9 from MDSCs.
Stimulation of bone marrow myeloid cells with bacterial
endotoxin LPS induces release of S100A8/A9 proteins from the
cytosol (21). We found that Gr1+CD11b+ cells from early septic
mice released large amounts of S100A8/A9 proteins after stimulation with LPS (Figure 6C). In contrast, S100A8/A9 protein
release from late sepsis Gr1+CD11b+ MDSCs diminished after
LPS stimulation. This unexpected finding suggests a dichotomous
regulation of S100A8/A9 release with intracellular accumulation
during late vs. early sepsis.
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FIGURE 4 | The S100A9 knockout mice do not generate immunosuppressive Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs). Sepsis was induced by
cecal ligation and puncture (CLP), and mice were treated and sampled as described in Figure 2. The early and late sepsis groups, respectively, included mice that
were killed between days 1–5 and 6–28 after CLP. (A,B) Inhibition of MDSC expansion in the S100A9 knockout mice during late sepsis. Bone marrow (A) and
spleen cells (B) cells were harvested, stained with anti-Gr1 and anti-CD11b antibodies and analyzed by flow cytometry. Representative dot plots (right) and
percentages of cells gated on Gr1 and CD11b staining are shown. *p < 0.05 vs. sham; #p < 0.001 vs. sham; **p < 0.001 vs. WT. (C) Effect of MDSCs on T cell
proliferation. To determine the immunosuppressive effect of sepsis Gr1+ CD11b+ MDSCs, spleen CD4+ T cells were isolated from normal (naive) mice and labeled
with the fluorescent dye carboxy-fluorosceindiacetate, succinimidyl ester (CFSE) for 10 min at room temperature. Gr1+ CD11b+ cells were then cocultured (at 1:1
ratio) with CD4+ T cells. The culture was stimulated with anti-CD3 plus anti-CD28 antibodies (1 μg/ml/each). After 3 days, CD4+ T cell proliferation was determined
by the step-wise dilution of CFSE dye in dividing CD4+ T cells by flow cytometry. Percentages of cell proliferation were calculated as follow: % cell
proliferation = 100 × (count from T cell + Gr1+CD11b+ cell culture/count from T cell culture). *p < 0.001 vs. sham or early sepsis; **p < 0.001 vs. late sepsis WT.
(D) The culture supernatants were analyzed for IFNγ levels by ELISA. *p < 0.001 vs. sham or early sepsis; **p < 0.0001 vs. late sepsis WT. Data are means ± SD
(n = 4–6 mice per group) and are representative of three experiments. WT, wild type; KO, knockout.

MDSCs Lacking S100A9 Do Not Express
miR-21 and miR-181b during Late Sepsis

in early and late sepsis Gr1+CD11b+ cells, but its levels were
markedly reduced in late sepsis cells (data not shown), likely due
to lack of S100A9 in the cytosol. Together, these results suggest
that nuclear translocation of S100A9 in Gr1+CD11b+ MDSCs
during late sepsis prevents its secretion and pro-inflammatory
effects.
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Expression of miR-21 and miR-181b is induced in Gr1+CD11b+
cells during sepsis and promotes Gr1+CD11b+ cell expansion (24).
We reported that blocking miR-21 and miR-181b in septic mice by
administration of miRNA antagomiRs diminishes Gr1+CD11b+
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FIGURE 5 | The S100A8 and S100A9 protein secretion is inhibited during late sepsis despite normal expression levels. (A) Secreted S100A8 and S100A9 proteins
was determined by measuring their plasma levels using ELISA. (B) Levels of S100A8 and S100A9 mRNAs. Phagocytes were isolated from peripheral blood by
gradients of Histopage-1077 and Histopaque-1119, and mRNA levels were determined by real-time PCR. The S100A8 and S100A9 expression levels were
normalized to 18S rRNA. Data are means ± SD (n = 5–9 mice per group), and are representative of three experiments (*p < 0.001 vs. sham; **p < 0.001 vs. early
sepsis). (C) Levels of S100A8 and S100A9 proteins in phagocyte lysate were determined by immunoblotting. The membranes were first incubated with anti-S100A8
antibody. After washing (without stripping), the membranes were incubated with anti-S100A9 antibody. Cells were pooled from 2–3 mice per group. The early and
late sepsis groups, respectively, included mice that were killed between days 1–5 and 6–28 after cecal ligation and puncture. Representative blot (upper) and
densitometric analysis of blots from three experiments (lower) are shown. Values were normalized to β-actin, and are presented relative to sham (*p < 0.001 vs.
sham; **p < 0.05 vs. early sepsis).

FIGURE 6 | The S100A8 and S100A9 proteins are retained in Gr1+CD11b+ cells during late sepsis. Gr1+CD11b+ cells were isolated from the bone marrow cells by
positive selection. The early and late sepsis groups, respectively, included mice that were killed between days 1–5 and 6–28 after cecal ligation and puncture.
(A) Levels of S100A8 and S100A9 mRNAs. Total RNA was extracted from Gr1+CD11b+ cells, and mRNA levels were determined by real-time PCR. The S100A8
and S100A9 expression levels were normalized to 18S rRNA (*p < 0.001 vs. sham). (B) Levels of S100A8 and S100A9 proteins in Gr1+CD11b+ whole cell lysates
were determined by immunoblotting. Cells were pooled from 2–3 mice per group. Representative blot (upper) and densitometric analysis of blots from three
experiments (lower) are shown. Values were normalized to β-actin and are presented relative to sham (*p < 0.01 vs. sham; **p < 0.05 vs. sham). (C) Protein
secretion after stimulation with lipopolysaccharide (LPS). Gr1+CD11b+ cells were isolated from the bone marrow of septic mice and stimulated for 24 h with 1 µg/ml
LPS (E. coli serotype 0111:B4). Levels of S100A8 and S100A9 in the culture supernatants were determined by ELISA. Data in A and C are means ± SD (n = 5–6
mice per group), and are representative of three experiments (**p < 0.0003 vs. early sepsis).

MDSC expansion during late sepsis response (24). Accordingly,
we measured miR-21 and miR-181b levels by RT-PCR in early
and late sepsis. Levels of miR-21 and miR-181b in Gr1+CD11b+
cells were increased during early sepsis in both wild-type and
knockout mice (Figure 8A). In late sepsis Gr1+CD11b+ cells, both
Frontiers in Immunology | www.frontiersin.org

miRNAs further increased in wild-type mice, but diminished in
S100A9 knockout mice.
We previously reported that miR-21 and miR-181b induction
during sepsis is dependent on both C/EBPβ expression and
Stat3 phosphorylation, which synergize to activate miR-21 and
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FIGURE 7 | The S100A9 protein phosphorylation and dimerization with S100A8 is inhibited and translocated to the nucleus in Gr1+CD11b+ cells during late sepsis.
Gr1+CD11b+ cells were isolated from the bone marrow cells by positive selection. The early and late sepsis groups, respectively, included mice that were killed
between days 1–5 and 6–28 after cecal ligation and puncture. Cell lysates were prepared, and expression of the indicated proteins was determined by
immunoblotting. (A) S100A9 phosphorylation was probed with anti-phospho threonine 113 antibody. To detect the S100A8/A9 heterodimer, the lysate was resolved
under non-denaturing conditions which produced a protein band of ~24 kDa. (B) Levels of p38 MAPK phosphorylation were determined using anti-phospho
tyrosine antibody that recognizes tyrosine number 180 and 182. (C) Levels of phosphorylated protein kinase C were determined using anti-phospho serines 643
and 660 antibodies. (D) Intracellular calcium levels were measured using a cell-based Fluo-4 NW calcium assay. Data are means ± SD of four mice per group and
are representative of two experiments. (E) Localization of the S100A9 protein. Nuclear and cytosolic proteins were extracted from Gr1+CD11b+ cells and
immunoblotted with the S100A9 antibody. Nuclear extracts were probed for p-S100A9. Membranes were re-probed with actin or nucleoporin antibody as a loading
control. In (A–C,E), cells were pooled from 2–3 mice per group. Representative blots [left; (A,C,E); upper, (B)] and densitometric analysis of blots from three
experiments are shown. Values were normalized to β-actin or nucleoporin, and are presented relative to sham [*p < 0.001 vs. sham; **p < 0.001 vs. early sepsis;
#
p < 0.001 vs. early sepsis S100A9 cytosolic; §p < 0.02 vs. early sepsis S100A9 nuclear (E)].

miR-181b promoters (37). To determine whether decreased miR21 and miR-181b expression in S100A9 knockout mice during
late sepsis is due to lack of C/EBPβ expression and/or Stat3 phosphorylation, we examined C/EBPβ and phosphorylated Stat3
protein levels in the Gr1+CD11b+ cell lysates. C/EBPβ expression
and Stat3 phosphorylation were similarly induced in wild-type
and S100A9 knockout mice (Figure 8B). We also reported
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that NFI-A expression is induced downstream of miR-21 and
miR-181b and promotes Gr1+CD11b+ cell expansion during
sepsis by attenuating myeloid cell differentiation and maturation
(31). Here, we detected NFI-A in Gr1+CD11b+ cells from early, but
not late septic S100A9 knockout mice (Figure 8B). These results
strongly support that S100A9 sustains both NFI-A and miR-21
and miR-181b levels during late sepsis immunosuppression.
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Administration of S100A8/A9 to S100A9
Knockout Mice Has No Impact on
Sepsis Response

S100A9 integrates two signaling pathways that facilitate
S100A8/9 release and may functionally dominate complex function (35). Other studies suggested that S100A8 may be dominant in the S100A8/A9 complex (21). Because S100A8 protein
is diminished in the S100A9 knockout mice (Figure 2C), we
examined whether reconstitution of the S100A9 knockout
mice with S100A8 and/or S100A9 affects late sepsis responses.
We injected (i.p.) the wild-type and S100A9 knockout mice with
recombinant mouse S100A8 and/or S100A9 at day 5 after CLP
(i.e., at the end of early sepsis phase). Administration of S100A8
alone or in combination with S100A9 did not affect survival of
the S100A9 knockout mice (Figure 9A). In the wild-type mice,
only injection of S100A8/A9 increased mortality by ~24–16%
between days 6 and 11 compared with mice injected with
saline (Figure 9B). In addition, we did not detect significant
changes in plasma levels of immunosuppressive cytokine IL-10
in mice treated with S100A8 or S100A8/A9, but levels of proinflammatory TNFα slightly increased in mice treated with
S100A8/A9 compared with S100A8 alone (Figure 9C). In the
wild-type mice, S100A8/A9 injection slightly, but significantly,
increased TNFα production. Of note, levels of IL-10 were
significantly higher compared with the S100A9 knockout mice,
and were further elevated after S100A8/A9 injection. These
results suggest that S100A8 absence in the S100A9 knockout
mice does not affect the inflammatory response to sepsis. These
results also suggest that administration of S100A8/A9 into
wild-type mice undergoing late sepsis can further enhance
immunosuppression.

S100A8/A9 Plasma Levels Decrease
in Chronic Septic Patients, but Remain
Elevated within Phagocytes

Secreted S100A8/A9 may promote acute and/or chronic inflammation (18). To determine whether S100A8/A9 expression in
sepsis patients correlates with sepsis inflammation, we first
measured plasma S100A8/A9 during human sepsis. Patients
were divided into two groups: the early septic group included
patients within 1–5 days of clinically detected sepsis and the
chronic sepsis group had been septic at least 6 days and up to
31 days. Figure 10A shows significant increases in S100A8/A9
plasma levels in the early septic group compared with healthy
controls. Notably, circulating S100A8/A9 levels decreased in
late septic patients. We then determined whether the decrease
in plasma levels of S100A8/A9 proteins correlated with reduced
protein expression by phagocytes. Using western blotting, we
observed marked increases in S100A8/A9 proteins in blood
phagocytes from early and late septic patients compared with
healthy controls (Figure 10B). We further examined whether
S100A9 expression correlates with sepsis prognosis for the late
septic group. Both mRNA and protein levels of S100A9 markedly
decreased in phagocytes from patients who later recovered from
chronic sepsis but remained elevated in those who eventually died

FIGURE 8 | The expression of miR-21 and miR-181b in Gr1+CD11b+ cells is
inhibited during late sepsis. The Gr1+CD11b+ cells were isolated from the
bone marrow of sham and septic mice using magnetic beads. The early and
late sepsis groups, respectively, included mice that were killed between days
1–5 and 6–28 after cecal ligation and puncture. (A) Measurements of miR-21
and miR-181b expression. MiRNA-enriched RNA was isolated, and levels of
miR-21 and miR-181b were determined by quantitative real-time qPCR using
miR-21 and miR-181b specific assay primers. Sample values were
normalized to U6 RNA as an internal control. Data are means ± SD (n = 3–5
mice per group), presented relative to values from sham mice (set at onefold).
Results are representative of three experiments (*p < 0.001 vs. sham;
**p < 0.001 vs. late sepsis WT). (B) Protein levels C/EBPβ, p-Stat3 and
NFI-A. Gr1+CD11b+ cell lysates were prepared and immunoblotted with
antibodies against the indicated proteins. Representative blots (upper) and
densitometric analysis of blots (lower) from three experiments is shown.
Values were normalized to β-actin, and are presented relative to sham
(*p < 0.01 vs. sham; **p < 0.05 vs. early sepsis).
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DISCUSSION
It is increasingly evident that MDSCs promote sepsis-induced
immunosuppression in mice (30, 38) and their counterparts
may contribute to the profound and sustained immunosuppression in human sepsis (7). Despite decades of studies on
sepsis pathobiology and multiple therapeutic failures, sepsis
is still a health-care crisis without available targeted treatment
options (8, 39). Importantly, the mediators that sustain MDSC
generation and immunosuppression in chronic sepsis remain
a mystery. This study, for the first time, introduces the concept
that S100A9 protein contributes to late sepsis mortality in mice
by its sustained expression and nuclear retention. Tantamount
to molecular targeting therapeutics, genetic deletion of S100A9
in mice improves chronic sepsis mortality. That this new paradigm may translate to human sepsis, we show that S100A8/A9
intracellular mRNA and protein levels in phagocytes are elevated
in patients with more chronic sepsis, and that a correlation may
exist between this repressor like phenotype and human sepsis
mortality. However, more research in humans is needed to test
this new theory before targeted therapy is developed. The emerging use of immune checkpoint, as well as metabolic checkpoint,
drugs (40, 41) may allow translation of our concept into both a
better understanding and treatment of human sepsis—a major
gap and health-care need.
We detected significantly elevated levels of S100A8/A9
proteins in the plasma of early septic mice, a known feature
of S100 proteins as pro-inflammatory, acute phase proteins
(15, 16). However, we showed that S100A8/A9 proteins in
septic mice decreased in the late sepsis phase, despite elevated
levels of mRNAs and proteins in circulating phagocytes and
Gr1+CD11b+ MDSCs in the bone marrow and spleens. Another
important observation supporting our paradigm was decreases
in immunosuppressive IL-10 cytokine and increased microbial
clearance from peritoneum in S100A9 knockout mice during late
sepsis. This supports that S100A9 directs immune suppression in
phagocytes and MDSCs. However, the mechanistic link between
miR-21 and miR-181b expression, as well as the signaling regulatory path involving C/EBPβ and NFI-A, supports that S100A9
acts as a transcription co-factor or an indirect epigenetic mediator. Epigenetic pathways like those regulated by NAD+ Sirtuins
1 and 6 (12) are candidates, as well as direct cooperativity with
transcription repressor complexes like RelB (42, 43).
Our study does not refute the substantive reports showing
S100A8/A9 proteins function mainly as extracellular proinflammatory mediators (14–16). A recent study showed that
S100A8/A9 proteins promote septic shock in mice via activating
TLR4 on innate immunity cells (21). Other findings support that
S100A8/A9 proteins also exert anti-inflammatory effects (22),
and our data suggest a dual role for S100A9 protein. Intracellular
S100A9 may act as an anti-inflammatory/immunosuppressive
mediator through reprogramming the Gr1+CD11b+ myeloid
cells into MDSCs, whereas extracellular S100A9 may promote
inflammation in the plasma and when secreted by phagocytes.
This interpretation of dual functioning proteins is not without precedent. For example, we previously discovered that
HMGB1 histone binding protein, which like S100A9 induces

FIGURE 9 | Administration of rS100A8/9 into the S100A9 knockout mice
undergoing sepsis has no effect on sepsis survival or inflammatory cytokine
production. Sepsis was induced by cecal ligation and puncture (CLP), and
mice were treated as described in Figure 2. On day 5 and day 6 after CLP,
mice were injected (i.p.) with 50 µg each of recombinant mouse S100A8 and/
or S100A9 protein or 100 µl saline. (A,B) Kaplan–Meier survival curves
showing deaths during the early and late sepsis phases in KO and WT mice
(n = 15 per group). (C) Plasma levels of TNFα and IL-10. Blood was collected
at day 15 after CLP from the KO mice (n = 6 mice per group) and at days
7–18 from the WT mice (n = 4–6 mice per group). Plasma was collected, and
levels of TNFα and IL-10 were determined by ELISA. Data are means ± SD.
*p < 0.05 vs. KO; **p < 0.001 vs. KO; #p < 0.0001 vs. KO; §p < 0.01 vs.
saline or rS100A8 WT. r, recombinant.

(Figures 10C,D). Together, these results suggest that sustained
intracellular S100A9 in phagocytes and perhaps MDSCs promote
chronic sepsis by sustaining immunosuppression.
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FIGURE 10 | Release of S100A8/A9 proteins is blocked in late septic patients. Blood phagocytes and plasma were isolated by gradients of Histopage-1077 and
Histopaque-1119 (Sigma). (A) Levels of S100A8/A9 proteins in plasma were determined by ELISA (run in duplicate). Data are means ± SD (n = 8 subjects/
group) (*p < 0.001 vs. HC; **p < 0.001 vs. early septic). (B) levels of S100A8/A9 proteins in phagocytes lysates were determined by western blot.
Representative blot (left) and densitometric analysis of blots (right) are shown. Results are representative of three immunoblots (*p < 0.01 vs. HC; *p < 0.05 vs.
early septic). (C,D) The late septic patient group shown in panel (A) was divided into two sub-groups: those who later recovered (n = 5) from sepsis or died
(n = 3). Their frozen phagocytes were divided. A portion of the cells was used for RNA extraction and determination of S100A8/A9 mRNA levels by real-time
PCR, and expression levels were normalized to 18S rRNA (C) (*p < 0.001). The remainder of the cells were lysed and S100A9 protein levels were determined by
western blot (D). Representative blots (left) and densitometric analysis of blots (right) are shown. Results are representative of three immunoblots (*p < 0.01).
Patient numbers are shown on top of the blots. Early septic included patients who were within 1–5 days after diagnosis. Late septic included patients who have
been septic for 6–31 days. HC, health control.

inflammation after release and through stimulation of TLR4,
is also an epigenetic repressor during endotoxin tolerance in
human monocytes, a biomarker of immunosuppression (44). Of
note, administration of recombinant S100A8 and/or S100A9 at
the onset of the late sepsis phase did not impact sepsis outcomes
in the S100A9 knockout mice. However, S100A8/A9 enhanced
mortality in the wild-type mice for the first few days after the
injection, and this response was accompanied by increases in the
levels of immunosuppressive IL-10 production.
Many MDSCs accumulate during late sepsis in mice (30, 38).
Our finding that S100A9 knockout mice did not generate immunosuppressive Gr1+CD11b+ cells (i.e., MDSCs) during late sepsis
response is physiologically significant, and supports that S100A9
is necessary for chronic MDSC repressor function. Moreover,
S100A9 knockout mice in early sepsis response were still able to
generate normal (immune competent) Gr1+CD11b+ cells, similar
to wild-type mice. While these functionally competent myeloid
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cells were phenotypically similar to the MDSCs generated in
late sepsis, they did not suppress T cell activation or proliferation. Thus, S100A9 protein reprograms immature Gr1+CD11b+
myeloid cells into MDSCs in late sepsis, but has no impact on
myeloid cell phenotype or functions under normal conditions or
during the early phase of sepsis.
S100A9 protein phosphorylation and dimerization with
S100A8 and subsequent secretion require phosphorylation
on S100A9 by p38 MAPK (32, 33) and activation of PKC in a
Ca2+-dependent manner (16). Our results showed that S100A9
protein phosphorylation and dimerization were inhibited in
the Gr1+CD11b+ cells from late, but not early, septic mice
despite normal activation of p38 and PKC throughout the sepsis
course. In addition, we did not observe changes in the intracellular Ca+2 levels. Most importantly, we found that S100A9
protein was mainly localized in the nuclear compartment in late
sepsis Gr1+CD11b+ cells (i.e., MDSCs). S100A8/A9 proteins
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